Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETHZ NASDAQ:PMN NASDAQ:SKYE NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$5.20+2.6%$4.65$0.70▼$17.46$98.86M1.176.44 million shs297,949 shsPMNPromis Neurosciences$10.53+2.7%$10.56$6.27▼$39.75$91.92M-0.1918,409 shs4,558 shsSKYESkye Bioscience$0.68-4.0%$0.80$0.57▼$5.75$24.90M2.95179,174 shs148,878 shsVRCAVerrica Pharmaceuticals$6.84+10.1%$6.33$3.28▼$9.82$106.68M1.4938,357 shs113,860 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition+0.80%-0.20%+11.67%+77.89%+506,999,900.00%PMNPromis Neurosciences+0.10%-2.75%-1.06%-30.46%-15.46%SKYESkye Bioscience+4.33%+0.16%-13.83%+22.77%-80.80%VRCAVerrica Pharmaceuticals+6.15%+10.30%+3.16%+41.78%+3.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETHZFlag Ship Acquisition$5.20+2.6%$4.65$0.70▼$17.46$98.86M1.176.44 million shs297,949 shsPMNPromis Neurosciences$10.53+2.7%$10.56$6.27▼$39.75$91.92M-0.1918,409 shs4,558 shsSKYESkye Bioscience$0.68-4.0%$0.80$0.57▼$5.75$24.90M2.95179,174 shs148,878 shsVRCAVerrica Pharmaceuticals$6.84+10.1%$6.33$3.28▼$9.82$106.68M1.4938,357 shs113,860 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETHZFlag Ship Acquisition+0.80%-0.20%+11.67%+77.89%+506,999,900.00%PMNPromis Neurosciences+0.10%-2.75%-1.06%-30.46%-15.46%SKYESkye Bioscience+4.33%+0.16%-13.83%+22.77%-80.80%VRCAVerrica Pharmaceuticals+6.15%+10.30%+3.16%+41.78%+3.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETHZFlag Ship Acquisition 1.00SellN/AN/APMNPromis Neurosciences 2.60Moderate Buy$26.50151.66% UpsideSKYESkye Bioscience 2.50Moderate Buy$8.501,150.18% UpsideVRCAVerrica Pharmaceuticals 2.25Hold$14.50111.99% UpsideCurrent Analyst Ratings BreakdownLatest SKYE, ETHZ, VRCA, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/11/2026PMNPromis Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/9/2026PMNPromis Neurosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/8/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/26/2026VRCAVerrica Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.005/20/2026PMNPromis Neurosciences Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/11/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/7/2026VRCAVerrica Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETHZFlag Ship Acquisition$4.11M24.05N/AN/A$29.12 per share0.18PMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/ASKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/AVRCAVerrica Pharmaceuticals$35.58M3.30N/AN/A$1.55 per share4.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/APMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)SKYESkye Bioscience-$55.92M-$1.44N/AN/AN/AN/A-217.27%-162.39%N/AVRCAVerrica Pharmaceuticals-$17.89M-$1.03N/AN/AN/A-47.97%-1,077.78%-40.76%8/11/2026 (Estimated)Latest SKYE, ETHZ, VRCA, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A5/12/2026Q1 2026VRCAVerrica Pharmaceuticals-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million5/11/2026Q1 2026SKYESkye Bioscience-$0.29-$0.32-$0.03-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthETHZFlag Ship AcquisitionN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETHZFlag Ship Acquisition1.1110.0710.07PMNPromis NeurosciencesN/A9.929.92SKYESkye BioscienceN/A1.781.78VRCAVerrica Pharmaceuticals0.032.101.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETHZFlag Ship Acquisition4.07%PMNPromis Neurosciences50.13%SKYESkye Bioscience21.09%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipETHZFlag Ship Acquisition15.10%PMNPromis Neurosciences1.50%SKYESkye Bioscience6.20%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/APMNPromis Neurosciences58.97 million8.83 millionNot OptionableSKYESkye Bioscience1135.14 million32.97 millionOptionableVRCAVerrica Pharmaceuticals4017.18 million7.90 millionNo DataSKYE, ETHZ, VRCA, and PMN HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...June 23 at 7:13 PM | markets.businessinsider.comVerrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common WartsJune 22, 2026 | quiverquant.comQVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common WartsJune 22, 2026 | globenewswire.comWall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to HoldJune 20, 2026 | americanbankingnews.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comVerrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...May 13, 2026 | uk.finance.yahoo.comVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comVerrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2026 | zacks.comVerrica Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the ...May 6, 2026 | theglobeandmail.comVerrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual MeetingMay 5, 2026 | globenewswire.comVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate ...May 5, 2026 | bakersfield.comBVerrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026May 5, 2026 | globenewswire.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the ...April 10, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual MeetingApril 9, 2026 | globenewswire.comVerrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. - VRCAMarch 21, 2026 | tmcnet.comVRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law FirmMarch 20, 2026 | businesswire.comVRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCAMarch 20, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSKYE, ETHZ, VRCA, and PMN Company DescriptionsFlag Ship Acquisition NASDAQ:ETHZ$5.20 +0.13 (+2.56%) As of 06/25/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Promis Neurosciences NASDAQ:PMN$10.53 +0.28 (+2.73%) Closing price 04:00 PM EasternExtended Trading$10.67 +0.14 (+1.33%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Skye Bioscience NASDAQ:SKYE$0.68 -0.03 (-4.02%) Closing price 04:00 PM EasternExtended Trading$0.68 +0.01 (+0.75%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Verrica Pharmaceuticals NASDAQ:VRCA$6.84 +0.63 (+10.14%) Closing price 04:00 PM EasternExtended Trading$6.75 -0.09 (-1.30%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab's NASA Win Tests Key Support After Sharp Pullback BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Xcel Energy Stock Offers Stability as Electricity Demand Builds Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
